Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Arena Scores Hefty Obesity Drug Deal With Eisai Ahead Of PDUFA Date

This article was originally published in The Pink Sheet Daily

Executive Summary

In addition to upfront and milestone payments, deal also includes effective royalties above 30 percent of annual net sales.
Advertisement

Related Content

Arena Says Patient Programs Will Offset Belviq’s Premium Price For Some
Belviq Gains FDA Approval For Weight Loss, But DEA Review Will Delay Launch
FDA Issues Complete Response Letter for Arena's Lorcaserin
FDA Issues Complete Response Letter for Arena's Lorcaserin
Deals Of The Week: Pfizer/FoldRx, Takeda/Orexigen, Bayer/Kythera ...
Deals Of The Week: Pfizer/FoldRx, Takeda/Orexigen, Bayer/Kythera ...
Takeda Bulks Up In Obesity With Orexigen Deal
Deals Of The Week: Sanofi/TargeGen, Arena/Eisai, GSK/Genmab ...
Arena Gets Financing Boost, Lorcaserin Advisory Committee Date
Arena Gets Financing Boost, Lorcaserin Advisory Committee Date

Topics

Advertisement
UsernamePublicRestriction

Register

PS070872

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel